Search
Solifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigational[L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511] … Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
Categories: Drugs Used in Benign Prostatic HypertrophyRivastigmine
go.drugbank.com/drugs/DB00989ApprovedInvestigationalRivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. … Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type.
Categories: Compounds used in a research, industrial, or household settingAlectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalApproved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance … It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC
Lepirudin
go.drugbank.com/drugs/DB00001ApprovedWithdrawn[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. … [L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine
Istradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigational[L8237] This drug was first approved in Japan on 25 March 2013.[A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213] … [A184067] This region of the brain is highly involved in motor control.[A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease.
Autophagy
smpdb.ca/view/SMP0578913Signalingthe fasted state), calcium/calmodulin‑dependent protein kinase kinase 2 (CAMKK2) directly phosphorylates and activates AMPK, which in turn phosphorylates ULK1 to trigger phagophore formation in an mTOR‑independent … An increased AMP:ATP ratio activates AMPK and concurrently inhibits mTORC1, resulting in dephosphorylation and activation of ULK1 kinase activity to nucleate the phagophore.
Enzymes: Activating molecule in BECN1-regulated autophagy protein 199mTc-14 F7 Mab
go.drugbank.com/drugs/DB05867Experimental99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo.
Fenfluramine
go.drugbank.com/drugs/DB00574ApprovedIllicitInvestigationalWithdrawnfrom the market in 1997. … It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression.
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIt was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Inositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnNicotinic acid plays an essential role in many important metabolic processes and has been used as lipid-lowering agent. … It is used in food supplements as a source of niacin (vitamin B3), where hydrolysis of 1 g (1.23 mmol) inositol hexanicotinate yields 0.91 g nicotinic acid and 0.22 g inositol.